Introduction
============

Lung cancer is the leading cause of cancer-associated mortality. It was estimated that 155,870 mortalities due to lung cancer occurred in the United States in 2017, which accounted for more than a quarter (26%) of all cancer mortalities ([@b1-ol-0-0-9221]). Patients with non-small cell lung cancer (NSCLC) approximately account for 80% of lung cancer cases ([@b2-ol-0-0-9221]). Surgical resection is the best treatment modality for localized lung cancer. However, 79% of lung cancer cases are diagnosed at an advanced stage. The cure rate of patients with advanced lung cancer using conventional chemotherapy is low ([@b3-ol-0-0-9221],[@b4-ol-0-0-9221]).

Tumor-associated genetic alterations have essential roles in the tumorigenesis and progression of lung cancer ([@b5-ol-0-0-9221]). Extensive study has been focused on finding oncogenes for the early diagnosis or effective therapy for lung cancer. Several drugs that target molecular signaling pathways have been applied to lung cancer treatment, particularly for advanced lung cancer. For example, erlotinib, gefitinib and afatinib worked efficiently for treating lung cancer cases with epidermal growth factor receptor mutations ([@b6-ol-0-0-9221]--[@b8-ol-0-0-9221]). Crizotinib is an anaplastic lymphoma kinase inhibitor for treating lung cancer cases with ROS1 translocations ([@b9-ol-0-0-9221]). However, the molecular pathogenesis of lung cancer has not been fully elucidated. Therefore, finding novel key genes that are associated with tumor progression and prognosis to further understand the molecular mechanisms of lung cancer is necessary.

Replication factor C (RFC), also known as activator 1, was originally purified from the extraction of HeLa cells at the end of 1980s ([@b10-ol-0-0-9221]). RFC was reported to be a necessary factor for DNA replication of simian virus 40 *in vitro* ([@b11-ol-0-0-9221]). One large subunit (RFC1/RFC140) and four small subunits (RFC2/RFC37, RFC3/RFC36, RFC4/RFC40 and RFC5/RFC38) make up the RFC complex and they were commonly found in numerous eukaryotes ([@b12-ol-0-0-9221],[@b13-ol-0-0-9221]). RFC functions as a clamp loader, which has a crucial role in loading proliferating cell nuclear antigen (PCNA) onto primed DNA to elongate the DNA chain ([@b14-ol-0-0-9221],[@b15-ol-0-0-9221]).

Several RFC proteins have been found to be involved in promoting cell proliferation in multiple carcinomas ([@b16-ol-0-0-9221]--[@b20-ol-0-0-9221]). Among them, RFC5 subunit has been demonstrated to interact with chromosome transmission fidelity protein 18 homolog (CTF18), This type of interaction not only have a role in sister chromatid cohesion but also stabilize the genome ([@b21-ol-0-0-9221],[@b22-ol-0-0-9221]). Peng *et al* ([@b23-ol-0-0-9221]) reported that RFC5 mediated resistance to temozolomide in glioma cells, which was independent of methylguanine-DNA methyltransferase, and its expression was positively regulated by forkhead box M1 ([@b23-ol-0-0-9221]). The upregulation of the RFC5 gene in multidrug-resistant leukemia cells compared with parental HL-60 cell indicated that RFC5 might participate in drug resistance ([@b24-ol-0-0-9221]). However, the molecular mechanisms underlying lung cancer and the prognostic value of RFC5 remain to be reported.

The present study aimed to identify whether RFC5 has a key role in promoting lung cancer progression and to investigate its biological function. Furthermore, the prognostic implication was also evaluated by using bioinformatic approaches. Our results showed that RFC5 might serve as an independent predictor for prognosis and a potential therapeutic target for lung cancer.

Materials and methods
=====================

### Utilization of expression profile datasets

All lung cancer microarray data with large sample sizes were downloaded from the National Center for Biotechnology Information (National Institutes of Health, Bethesda, MD, USA) Gene Expression Omnibus database (GEO; <http://www.ncbi.nlm.nih.gov/geo/>). The relative expression levels of RFC5 and clinical characteristics as well as follow-up information were extracted for statistical analysis. The probes corresponding to RFC5 were '203210_at' and '203209_at' with which the expression of RFC5 was traced. The basic features of the database were summarized in [Table I](#tI-ol-0-0-9221){ref-type="table"}. In addition, ONCOMINE was used to compare RFC5 expression levels in multiple datasets between cancer specimens and normal specimens. Cluster analysis of RFC5 expression between lung cancer histological subtypes and normal lung tissues was further performed across 6 analyses. The thresholds, two-fold change, P\<0.001 and the top 10% gene rank, were used to reduce the false discovery rate (FDR). The ONCOMINE data are available from <https://www.oncomine.org>.

### Tissue samples and RNA extraction

A total of 26 lung cancer and matched adjacent lung cancer tissues were collected from patients with primary lung cancer surgical resection at the Renmin Hospital of Wuhan University (Hubei, China) from May to July 2017. None of the patients received chemotherapy or radiotherapy prior to operation. The present study was approved by the Ethics Committee of Renmin Hospital of Wuhan University. Written informed consents were obtained from all patients prior to enrollment in the study and anonymity was guaranteed. All samples were immediately cut into pieces and stored in liquid nitrogen. Total RNA was extracted from tissue using TRIzol and quantified by NanoDrop 2000 (Thermo Fisher Scientific, Inc., Waltham, MA, USA).

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Reverse transcription was performed using 2 µg total RNA with the RevertAid RT Reverse Transcription kit (Thermo Fisher Scientific, Inc.). According to the manufacturer\'s protocol, qPCR was performed using the QuantStudio 6 Flex Real-Time PCR system (Thermo Fisher Scientific, Inc.) with SYBR Premix Ex Taq™ II (Takara Bio, Inc., Otsu, Japan). The cycling parameters were 50°C for 30 min, 94.5°C for 15 min, then 40 cycles of 96°C for 30 sec and 59.7°C for 1 min. The sequences of the primers are as follows: RFC5 forward, 5′-GAAGCAGACGCCATGACTCAG-3′ and reverse, 5′-GACCGAACCGAAACCTCGT-3′; β-actin forward, 5′-GAAGAGCTACGAGCTGCCTGA-3′ and reverse, 5′-CAGACAGCACTGTGTTGGCG-3′. The relative expression levels of RFC5 were quantified using RT-qPCR and the 2^−ΔΔCq^ method in triplicate and normalized to β-actin ([@b25-ol-0-0-9221]).

### Gene set enrichment analysis (GSEA)

GSEA was performed using a Java GSEA desktop application that was downloaded from <http://www.broad.mit.edu/gsea/>. The GSE3141 dataset was analyzed with the GMT file (c5.all.v5.1) gene set, to obtain biological processes enriched by RFC5. The samples were divided into a high RFC5 expression group (top 50%) and a low RFC5 expression group (bottom 50%). A total of four files including expression datasets, gene sets, phenotype labels and chip platforms were loaded for running GSEA according to the manufacturer\'s specifications. Significant gene sets were confirmed with nominal P-value \<0.05 and FDR \<0.25.

### Kaplan-Meier plotter database analysis

Kaplan-Meier plotter ([www.kmplot.com](www.kmplot.com)) was used to assess the prognostic significance of RFC5 expression in lung cancer. The database includes gene expression data and clinicopathological features of lung ([@b26-ol-0-0-9221]), breast ([@b27-ol-0-0-9221]), ovarian ([@b28-ol-0-0-9221]) and gastric cancer ([@b29-ol-0-0-9221]). In order to evaluate the prognostic value of RFC5, the patient samples were divided into two groups, high expression and low expression, on the basis of the median expression of the RFC5 (high expression, top 50%; low expression, bottom 50%). The Kaplan-Meier survival plots were obtained by entering the survival time \[overall survival (OS), first progression (FP) and post-progression survival (PPS)\] of patients with NSCLC, respectively. The P-values of the log-rank test and hazard ratio (HR) with 95% confidence intervals (CIs) were also calculated.

### Statistical analysis

Statistical analyses were performed with GraphPad Prism (version 5.0; GraphPad Software, Inc., La Jolla, CA, USA) and SPSS (version 19.0; SPSS, Inc., Chicago, IL, USA). A paired t-test was used to compare the differences between the expression level of RFC5 in tumor and adjacent normal tissues. An unpaired t-test was used for unpaired comparisons. The comparisons between the experimental groups and the healthy group were performed using one-way ANOVA followed by Dunnett\'s multiple comparisons test. The P-values were derived from ranked data as variance was unequal among groups (Bartlett\'s test, P\<0.05), and the values were adjusted by Bonferroni\'s test. The associations between RFC5 expression and clinicopathological parameters were analyzed using the χ^2^ test. Cox regression was used for univariate and multivariate analysis to determine the independent factors that have a significant effect on patient survival. The HR and 95% CIs of the prognostic factors were calculated. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### RFC5 is upregulated in multiple types of cancer

The ONCOMINE database was used to compare the levels of RFC5 expression in cancer and normal samples. The results indicated that RFC5 was overexpressed in multiple cancer types ([Fig. 1A](#f1-ol-0-0-9221){ref-type="fig"}). Among 20 common types of cancer, the upregulation of RFC5 was identified in 14 cancer types. The GEO database was searched to analyze the differences in RFC5 expression levels in various tumors. As indicated in [Fig. 1B](#f1-ol-0-0-9221){ref-type="fig"}, RFC5 was upregulated in breast carcinoma (P\<0.0001), esophageal cancer (P\<0.0001), lung tumor (P\<0.0001), gastric cancer (P\<0.0001), colorectal cancer (P=0.0022), bladder tumor (P=0.0134), cervical cancer (P\<0.0001) and nasopharyngeal carcinoma (P\<0.0001) tissues compared with normal tissues. These data indicated that RFC5 was upregulated in a variety of tumor types, which suggested it might be relevant to the oncogenesis of these tumors.

### RFC5 is significantly overexpressed in lung cancer

The publicly available GEO datasets were used to analyze the expression levels of RFC5 mRNA in cancer and normal tissues. Compared with normal tissues, the expression levels of RFC5 were significantly higher in lung tumor ([Fig. 2A](#f2-ol-0-0-9221){ref-type="fig"}), NSCLC ([Fig. 2B](#f2-ol-0-0-9221){ref-type="fig"}), paired tumor ([Fig. 2C and D](#f2-ol-0-0-9221){ref-type="fig"}), lung adenocarcinoma (ADC), squamous cell carcinoma (SCC) and large cell carcinoma (LCC) tissues ([Fig. 2E](#f2-ol-0-0-9221){ref-type="fig"}). Furthermore, RFC5 was uniformly upregulated in six analyses in ONCOMINE. The level of RFC5 expression was confirmed in 26 paired cancerous and adjacent normal tissues from patients with lung cancer by RT-qPCR. Consistent with the findings of previous bioinformatic analyses, RFC5 was significantly overexpressed in lung cancer tissue compared with adjacent tissues.

### RFC5 expression is associated with the clinicopathological characteristics of lung cancer

In order to elucidate the association between RFC5 expression and the clinicopathological characteristics of lung cancer, the GSE30219 dataset was analyzed by χ^2^ test. RFC5 expression was associated with sex (P=0.0300), T stage (P\<0.0001), N stage (P\<0.0001) and relapse (P=0.0010). However, there were no significant associations between RFC5 expression with age (P=0.5580) and M stage (P=0.2820; [Table II](#tII-ol-0-0-9221){ref-type="table"}). These results demonstrated that RFC5 expression was associated with the progression of lung cancer.

### High expression of RFC5 indicates a poor prognosis

To further investigate the association between RFC5 expression and the outcomes of patients with lung cancer, Kaplan-Meier analysis was applied to assess the OS, FP and PPS in the high RFC5 expression and low RFC5 expression groups. As shown in [Fig. 3A-C](#f3-ol-0-0-9221){ref-type="fig"}, a high expression of RFC5 corresponded to a poorer OS (HR, 1.65; 95% CI, 1.45--1.88; P=1.1×10^−14^), FP (HR, 1.34; 95% CI, 1.04--1.73; P=0.023) and PPS (HR, 1.62; 95% CI, 1.34--1.97; P=7.5×10^−7^), respectively. Kaplan-Meier analysis was performed in three GEO datasets (GSE30219, GSE31210 and GSE37745, respectively), which consistently indicated that a low RFC5 expression was associated with improved OS ([Fig. 3D-F](#f3-ol-0-0-9221){ref-type="fig"}). Furthermore, univariate and multivariate Cox regression analyses were performed to investigate the independent factors that affect patient survival. As shown in [Table III](#tIII-ol-0-0-9221){ref-type="table"}, the high RFC5 expression group exhibited a significantly increased risk of OS (HR, 2.027; 95% CI, 1.498--2.742, P\<0.0001) compared with the low RFC5 expression group. The characteristics that were significant in the univariate analyses were then incorporated into the multivariate analyses. Age (HR, 2.014; 95% CI, 1.478--2.744, P\<0.0001), T stage (HR, 1.363; 95% CI, 1.106--1.678, P\<0.0040) and RFC5 expression (HR, 1.557; 95% CI, 1.137--2.132, P\<0.0060) were indicated to be significant risk factors in multivariate analysis and were determined as independent prognostic factors of OS. These results also indicated that RFC5 expression (HR, 1.736; 95% CI, 1.143--2.636, P \<0.0100); T stage (HR, 1.461; 95% CI, 1.137--1.878, P\<0.0030) and N stage (HR, 1.461; 95% CI, 1.016--2.100, P\<0.0410) were independent prognostic factors for disease-free survival ([Table IV](#tIV-ol-0-0-9221){ref-type="table"}).

### RFC5 enhances the proliferation of tumor cells in lung cancer

GSEA was used to analyze the biological processes of RFC5 in lung cancer. The GSE3141 dataset was analyzed with GMT file C5 (GO gene set). The first 20 relevant biological processes that met P-value \<0.05 and false discovery rates \<0.25 are shown in [Table V](#tV-ol-0-0-9221){ref-type="table"}. The results showed that several gene sets that are associated with cell cycle and DNA damage were enriched in the RFC5 overexpression group, which suggested the RFC5 is involved in the proliferation of lung cancer cells ([Fig. 4](#f4-ol-0-0-9221){ref-type="fig"}).

Discussion
==========

There is no doubt that DNA replication is a crucial process during cell proliferation and enables the ability to proliferate indefinitely, which is a hallmark of tumor cells ([@b5-ol-0-0-9221]). A number of genes that are associated with DNA replication are deregulated in cancer cells. Therefore, the present study focused on RFC, which is involved in DNA replication and damage repair as well as cell division and proliferation ([@b30-ol-0-0-9221]--[@b34-ol-0-0-9221]). In general, RFC is a structurally specific DNA-binding protein that preferentially binds to the 3′ end of the template primer. A study has indicated that RFC catalyzed the formation of a cyclic structure of PCNA around the primers in an ATP-dependent manner ([@b35-ol-0-0-9221]). Munshi *et al* ([@b36-ol-0-0-9221]) observed that cyclin-dependent kinases reduced the stability of RFC, inactivating it in the S phase to regulate DNA replication ([@b36-ol-0-0-9221]). However despite being an important component of the RFC, the role of RFC5 in lung cancer remains unknown. Therefore, the present study investigated the expression patterns, potential biological functions and the prognostic value of RFC5 in lung cancer.

Bioinformatics is a multidisciplinary research field, and bioinformatic analysis is particularly used for developing methods and software tools to identify candidate genes. Such understanding allows the efficient elucidation of the genetic basis of diseases ([@b37-ol-0-0-9221]). In the present study, the ONCOMINE database and GEO datasets were applied to analyze RFC5 expression in lung cancer. The results suggested that RFC5 was highly expressed in lung cancer samples compared with normal samples. The expression levels of RFC5 in 26 paired samples were confirmed by RT-qPCR, and consistent results were attained.

To date, conventional surgery and chemotherapy remain the main treatment modalities for treating lung cancer ([@b38-ol-0-0-9221]). However, numerous lung cancer cases are diagnosed at an advanced stage. When treating patients with advanced lung cancer using conventional surgical resection and chemotherapy, the 5-year relative survival rate is only 4% ([@b3-ol-0-0-9221]). Therefore, it is important to find a novel target molecule that can be used to diagnose and used for therapy. The prognostic value of RFC5 was rarely investigated in previous studies. In the present study, RFC5 was identified to be a potential independent prognostic factor for patients with lung cancer. A higher expression of RFC5 was significantly associated with higher T stage, more advanced regional lymph node metastasis and a higher probability of relapse. These findings suggested a potential role of RFC5 in the progression of lung cancer, which might contribute to the development of accurate diagnosis and personalized treatment strategies.

A number of studies revealed the association between RFC5 overexpression and DNA replication. The GSEA provides an improved understanding of the biological functional enrichment in the high RFC5 expression groups. The gene sets that were most significant were associated with DNA replication or DNA damage, which suggested that RFC5 might promote the proliferation of lung cancer cells. A study of other RFC subunits found that the interaction between RFC2, RFC3 and c-myc promoted cell division ([@b39-ol-0-0-9221]). Furthermore, cDNA microarray analysis and meta-analysis confirmed that the RFC4 mRNA was abnormally high in a variety of malignant tumors, including ADC, cervical cancer, head and neck squamous cell carcinoma and colorectal cancer ([@b18-ol-0-0-9221],[@b40-ol-0-0-9221]--[@b43-ol-0-0-9221]). Chae *et al* ([@b17-ol-0-0-9221]) reported that RFC3 might promote cell proliferation, and its promoter directly binds with CAMP responsive element binding protein in acute myeloid leukemia. The copy number of RFC3 also reported to be increased in other types of cancer, and knocking out RFC3 was demonstrated to inhibit the growth of tumor cells. As the five RFC subunits possess similar conserved regions of ATP/GTP-binding proteins, each of the subunit has a remarkable degree of similarity ([@b13-ol-0-0-9221]); which further indicated that they might be involved in similar biological processes.

In conclusion, this is the first study to systematically demonstrate that RFC5 is an oncogene, which is closely associated with the prognosis of lung cancer. RFC5 was significantly overexpressed in lung cancer tissues compared with normal tissues. Furthermore, a high expression level of RFC5 was associated with poor clinicopathological characteristics and proliferation of tumor cells. In summary, RFC5 might serve as a prognostic biomarker and novel therapeutic target for lung cancer.
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![Analysis of RFC5 expression in various types of human cancer. (A) The ONCOMINE database was queried for RFC5 expression between cancer and normal specimens by using the criteria: Two-fold change for RFC5 expression, top 10% gene rank and P-value\<0.001. Red, RFC5 upregulation; blue, RFC5 downregulation. (B) RFC5 expression was visualized by using 10 publicly available Gene Expression Omnibus datasets. RFC5 expression was transformed into log2 (probe intensities) and presented as the mean ± standard error. \*P\<0.05; \*\*P\<0.01; \*\*\*P\<0.001. CNS, central nervous system; RFC5, replication factor C subunit 5.](ol-16-04-4201-g00){#f1-ol-0-0-9221}

![Identification of RFC5 as an overexpressed gene in lung cancer. (A-D) Comparison of the level of RFC5 mRNA expression between cancerous and normal tissue from the datasets (A) GSE30219, (B) GSE33532, (C) GSE19804 (paired samples) and (D) GSE32863 (paired samples). \*\*\*P\<0.001, paired t-test and unpaired t-test. (E) Expression level of RFC5 in ADC, SCC and LCC in the GSE19188 dataset. \*\*\*P\<0.001, one-way ANOVA and Dunnett\'s test. (F) Cluster analysis of RFC5 in different data sets of lung cancer subtypes. Red, significant overexpression. The P-value was calculated using the meta-analysis. (G) Expression levels of RFC5 mRNA in 26-paired lung cancer were assessed by RT-qPCR. (H) Comparison of the expression levels of RFC5 in lung cancer tissues and adjacent tissues. \*\*\*P\<0.001; RFC5, replication factor C subunit 5; ADC, adenocarcinoma; LCC, large cell carcinoma; SCC, squamous cell carcinoma.](ol-16-04-4201-g01){#f2-ol-0-0-9221}

![Prognostic values of RFC5 in NSCLC. The associations between RFC5 expression and (A) OS, (B) FP or (C) PPS rate in total samples were analyzed using the Kaplan-Meier Plotter database. (D-F) Overall survival curves for patients in (D) GSE30219, (E) GSE31210 and (F) GSE37745. FP, first progression; HR, hazards ratio; OS, overall survival; PPS, post progression survival; RFC5, replication factor C subunit 5.](ol-16-04-4201-g02){#f3-ol-0-0-9221}

![RFC5 enriched cell cycle and DNA damage process in lung cancer. Gene set enrichment analysis was performed by GSEA using the GSE3141 dataset. The gene profile of high RFC5 expression groups (top 50%) and low RFC5 expression groups (bottom 50%) were loaded to the GSEA software, and the 'c5.all.v5.1' gene set was selected to process the analysis. (A) RFC5 high expression enriched DNA replication, (B) replication fork, (C) mitotic cell cycle, (D) cell cycle process, (E) DNA repair, (F) response to DNA damage stimulus signature genes. GSEA, gene set enrichment analysis; NES, normal enrichment score; NOM P-value, normal P-value; FDR q-value, false discovery rate q-value.](ol-16-04-4201-g03){#f4-ol-0-0-9221}

###### 

Basic information of the 10 Gene Expression Omnibus datasets.

  Cancer type                    Accession no.   Number of samples (tumor/normal)   P-value
  ------------------------------ --------------- ---------------------------------- ----------
  Breast carcinoma               GSE10780        42/143                             \<0.0001
  Esophageal carcinoma           GSE23400        53/53                              \<0.0001
  Lung carcinoma                 GSE30219        293/14                             \<0.0001
  Gastric cancer                 GSE13861        71/19                              \<0.0001
  Acute lymphoblastic leukemia   GSE26713        117/7                              0.1439
  Colorectal cancer              GSE32323        17/17                              0.0022
  Bladder cancer                 GSE3167         41/9                               0.0134
  Melanoma                       GSE3189         45/25                              0.1813
  Cervical cancer                GSE14407        33/24                              \<0.0001
  Nasopharyngeal carcinoma       GSE12452        31/10                              \<0.0001

P-values were acquired using the t-test for the comparison of replication factor C 5 expression between cancer and normal tissues.

###### 

Associations between RFC5 expression and clinicopathological characteristics of patients with lung cancer in the GSE30219 dataset.

                     RFC5 expression                  
  ------------ ----- ----------------- ----- -------- -----------------------------------------------------
  Age                                        0.342    0.5580
    ≤62.0      146   71                75             
    \>62.0     146   76                70             
  Sex                                        4.711    0.0300
    Female     43    15                28             
    Male       250   132               118            
  T stage                                    29.997   \<0.0001
    T1         166   61                105            
    T2         69    42                27             
    T3-4       52    40                12             
  N stage                                    37.451   \<0.0001
    Positive   93    71                22             
    Negative   198   75                123            
  Metastasis                                 2.000    0.2820^[a](#tfn2-ol-0-0-9221){ref-type="table-fn"}^
    Yes        8     6                 2              
    No         282   140               142            
  Relapse                                    11.757   0.0010
    No         164   65                99             
    Yes        114   69                45             

Fisher\'s exact test. RFC5, replication factor C 5.

###### 

Univariate and Multivariate analysis of the effect of covariates on overall survival for patients with lung cancer in the GSE30219 dataset.

  A, Univariate analysis                                
  ------------------------------ ---------------------- -------------
  Age                                                   
    ≤62 vs. \>62 years           2.101 (1.544--2.858)   \<0.0001
  Sex                                                   
    Female vs. male              1.789 (1.098--2.916)     0.0200
  T stage                                               
    T1 vs. T2 vs. T3 vs. T4      1.589 (1.368--1.845)   \<0.0001
  N stage                                               
    N0 vs. N1                    1.770 (1.431--2.188)   \<0.0001
  M stage                                               
    M0 vs. M1                    2.456 (0.908--6.644)     0.0770
  RFC5 expression                                       
    High vs. low                 2.027 (1.498--2.742)   \<0.0001
                                                        
  **B, Multivariate analysis**                          
                                                        
  **Variables**                  **HR (95% CI)**        **P-value**
                                                        
  Age                                                   
    ≤62 vs. \>62 years           2.014 (1.478--2.744)   \<0.0001
  Sex                                                   
    Female vs. male              1.515 (0.926--2.478)     0.0980
  T stage                                               
    T1 vs. T2 vs. T3 vs. T4      1.363 (1.106--1.678)     0.0040
  N stage                                               
    N0 vs. N1                    1.259 (0.935--1.696)     0.1280
  M stage                                               
    M0 vs. M1                    --                     --
  RFC5 expression                                       
    High vs. low                 1.557 (1.137--2.132)     0.0060

CI, confidence interval; HR, hazard ratio; RFC5, replication factor C 5.

###### 

Univariate and multivariate analysis of the effect of covariates on disease-free survival for patients with lung cancer in the GSE30219 dataset.

  A, Univariate analysis                                 
  ------------------------------ ----------------------- -------------
  Age                                                    
    ≤62 vs. \>62 years           1.332 (0.902--1.968)      0.1490
  Sex                                                    
    Female vs. male              1.301 (0.740--2.286)      0.3610
  T stage                                                
    T1 vs. T2 vs. T3 vs. T4      1.852 (1.541--2.226)    \<0.0001
  N stage                                                
    N0 vs. N1                    2.309 (1.786--2.986)    \<0.0001
  M stage                                                
    M0 vs. M1                    3.705 (1.359--10.095)     0.0100
  RFC5 expression                                        
    High vs. low                 2.327 (1.563--3.464)    \<0.0001
                                                         
  **B, Multivariate analysis**                           
                                                         
  **Variables**                  **HR (95% CI)**         **P-value**
                                                         
  Age                                                    
    ≤62 vs. \>62 years           --                      --
  Sex                                                    
    Female vs. male              --                      --
  T stage                                                
    T1 vs. T2 vs. T3 vs. T4      1.461 (1.137--1.878)    0.0030
  N stage                                                
    N0 vs. N1                    1.461 (1.016--2.100)    0.0410
  M stage                                                
    M0 vs. M1                    2.640 (0.960--7.265)    0.0600
  RFC5 expression                                        
    High vs. low                 1.736 (1.143--2.636)    0.0100

CI, confidence interval; HR, hazard ratio; RFC5, replication factor C 5.

###### 

Enrichment of biological processes in the RFC5 high expression group.

  No.   GS details                                         Size   ES      NES     NOM P-value   FDR q-value
  ----- -------------------------------------------------- ------ ------- ------- ------------- -------------
    1   DNA replication                                    88     0.607   2.085   0.002         0.037
    2   Chromosomal part                                   88     0.667   2.083   \<0.001       0.020
    3   DNA-dependent DNA replication                      47     0.672   2.072   0.002         0.015
    4   Chromosome                                         114    0.632   2.071   \<0.001       0.012
    5   DNA metabolic process                              232    0.518   2.026   \<0.001       0.018
    6   Double-strand break repair                         22     0.739   2.013   0.002         0.019
    7   Nuclear part                                       487    0.527   1.988   \<0.001       0.024
    8   Nuclear membrane                                   47     0.651   1.985   \<0.001       0.022
    9   Nuclear pore                                       28     0.761   1.982   \<0.001       0.020
  10    Nuclear membrane part                              39     0.688   1.958   \<0.001       0.026
  11    Nuclear envelope                                   67     0.607   1.951   \<0.001       0.026
  12    Organelle lumen                                    391    0.512   1.940   \<0.001       0.027
  13    Membrane-enclosed lumen                            391    0.512   1.940   \<0.001       0.025
  14    Mitotic cell cycle                                 136    0.571   1.922   0.006         0.029
  15    DNA repair                                         117    0.533   1.918   \<0.001       0.029
  16    Envelope                                           158    0.587   1.912   \<0.001       0.030
  17    Organelle envelope                                 158    0.587   1.912   \<0.001       0.028
  18    Translation factor activity nucleic acid binding   29     0.696   1.908   \<0.001       0.029
  19    RNA splicing                                       66     0.651   1.907   \<0.001       0.027
  20    Cell cycle process                                 172    0.539   1.905   0.006         0.027

Statistical analyses were performed using the gene set enrichment analysis software. GS, gene sets; ES, enrichment score; NES, normal enrichment score; NOM, normal; FDR, false discovery rate; RFC5, replication factor C 5.

[^1]: Contributed equally
